Verge Genomics Earns $32M for AI Drug Discovery

Artificial intelligence (AI) is continuing to make waves in the life sciences industry, with today's announcement that a drug-discovery company called Verge Genomics has landed $32 million in Series A financing. Based in San Francisco, Verge Genomics uses machine learning and sprawling data sets to identify new therapeutics for neurological diseases. Since its founding in 2015, the startup has nurtured "lead therapeutic programs" and built proprietary genomic data sets for Parkinson's disease and amyotrophic lateral sclerosis (ALS). Investors nodded to those advances and Verge Genomics' roster of diverse experts when they announced the windfall. Read: Which Health-Tech Startups Are Making Money in 2018?